Hyderabad, India, August 20, 2025 – NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) today announced the launch of Bosentan Tablets for Oral Suspension (TFOS), 32mg, a generic version of Tracleer® developed by Actelion Pharmaceuticals US Inc. The launch is in collaboration with NATCO’s marketing partner, Lupin Limited, and comes with 180-day generic drug exclusivity in the United States.
Bosentan TFOS is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH. The therapy aims to improve pulmonary vascular resistance (PVR), which in turn is expected to enhance exercise ability and overall clinical outcomes.
Science Significance
Bosentan is a dual endothelin receptor antagonist that targets a critical pathway involved in pulmonary arterial hypertension (PAH). The oral suspension formulation is specifically designed for pediatric patients aged 3 years and older, providing a precise and convenient dosing alternative. This innovation not only improves treatment compliance but also represents a significant advance in translating complex cardiopulmonary science into accessible dosage forms tailored for children.
Regulatory Significance
The approval and launch of Bosentan TFOS underscore the importance of the Hatch-Waxman Act’s first-to-file provisions, which incentivize early generic challenges and ensure market competition. NATCO’s 180-day exclusivity period is a direct outcome of its regulatory agility and successful navigation of the U.S. FDA’s complex approval pathways. This reinforces the FDA’s commitment to expanding pediatric-friendly formulations in areas of high unmet medical need.
Advertisement
Business Significance
With estimated U.S. sales of USD 10 million for the 12 months ending June 2025, the market for Bosentan TFOS may appear niche but carries strategic weight. The 180-day exclusivity offers NATCO and Lupin a valuable opportunity to capture market share before additional generic competitors enter. This launch also signals NATCO’s growing presence in the U.S. generics segment, strengthening its portfolio in rare and orphan disease markets and enhancing revenue visibility in a competitive pharmaceutical landscape.
Patients’ Significance
For children living with PAH, treatment options have historically been limited, particularly in formulations suitable for younger patients. The availability of a cost-effective generic oral suspension will improve treatment accessibility, reduce financial burden on families, and expand therapeutic choices for pediatric cardiologists. Ultimately, this step brings renewed hope for improved quality of life and exercise capacity in young patients battling a rare and life-threatening disease.
Policy Significance
This launch highlights how global regulatory frameworks and intellectual property policies work to balance innovation and access. The U.S. exclusivity provisions not only reward early challengers but also accelerate patient access to lower-cost alternatives. It sets a precedent for how pediatric formulations of complex drugs can be incentivized and encourages more manufacturers to invest in child-friendly generics—an often underdeveloped area in pharmaceutical policy.
Transaction Highlights
NATCO holds first-to-file status for this formulation, securing its exclusivity period in the U.S. market. According to industry sales data, Bosentan TFOS 32mg recorded estimated sales of USD 10 million in the U.S. for the 12 months ending June 2025. The launch represents a significant milestone for NATCO and Lupin, reinforcing their commitment to providing affordable treatment options for rare and complex conditions while strengthening their presence in the U.S. generics market.
The entry of NATCO and Lupin’s Bosentan TFOS into the U.S. market marks a milestone where science, regulation, business, and patient need converge. By leveraging first-to-file exclusivity, the companies are delivering a much-needed treatment option for children with PAH, reaffirming their commitment to advancing affordable and accessible care in rare diseases.
Source: NATCO Pharma Press Release
